Amneal Pharmaceuticals, Inc. (AMRX) Institutional Ownership

Ownership Summary

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) appears in 271 institutional 13F filings for the quarter ending December 2025.

• These investors held 47.9% of outstanding shares in December 2025, up from 47.0% in September 2025.
• Their total shares held in AMRX increased 3.69% from the prior quarter, while the number of investors in Amneal Pharmaceuticals increased 37.56% year over year.
• Of these 271 holders, 152 added to their stakes in Amneal Pharmaceuticals, 81 trimmed positions, and 38 made no changes.
• Combined, these investors held 155.67Mn shares in AMRX for December 2025, up by 5.55Mn shares quarter on quarter, and up 26.55Mn shares year over year.
• As of December 31, 2025, BlackRock, Inc. held the largest stake in Amneal Pharmaceuticals with 24.52Mn shares, accounting for 7.55% of total shares outstanding.
• The biggest buyers of Amneal Pharmaceuticals for the quarter ending December 2025 included VANGUARD PORTFOLIO MANAGEMENT LLC (11.32Mn), BlackRock, Inc. (10.22Mn), VANGUARD CAPITAL MANAGEMENT LLC (7.59Mn), State Street Corp (2.68Mn), Invesco Ltd. (1.44Mn).
• The biggest sellers of Amneal Pharmaceuticals for the quarter ending December 2025 included CITADEL ADVISORS LLC (5.6Mn), MILLENNIUM MANAGEMENT LLC (2.99Mn), Goldman Sachs Group Inc (2.3Mn), Phocas Financial Corp. (1.56Mn), Rubric Capital Management LP (1.3Mn).
• According to Business Quant data, leading holders of AMRX for December 2025 are BlackRock, Inc. (24.52Mn), TPG GP A, LLC (12.33Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (11.32Mn), Rubric Capital Management LP (11.04Mn), VANGUARD CAPITAL MANAGEMENT LLC (7.59Mn), State Street Corp (6.79Mn), DIMENSIONAL FUND ADVISORS LP (5.69Mn), Morgan Stanley (4.64Mn), GEODE CAPITAL MANAGEMENT, LLC (4.55Mn), Neuberger Berman Group LLC (3.68Mn).